Drug intelligence / Profile preview

BSC-1601

Development stage: Unknown
Lead developer: BiSiChem
Modality: Small Molecules

Overview

BSC-1601 is a small molecule drug developed by BiSiChem Co. Ltd. It is currently in the discovery phase and has not yet entered clinical trials. The primary therapeutic areas under investigation for BSC-1601 are digestive system disorders, with active indications including fibrosis and nonalcoholic steatohepatitis (NASH). Specific details regarding its mechanism of action, molecular targets, or chemical structure have not been disclosed publicly as of the latest available information[2][4].

Beyond the preview

Go deeper on BSC-1601.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BSC-1601.

Explore the full profile